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Abstract 
We report here a novel role for Jun dimerization protein-2 (JDP2) as a regulator 
of the progression of normal cells through the cell cycle.  To determine the role of 
JDP2 in vivo, we generated Jdp2 knock-out (Jdp2KO) mice by targeting exon 1 to 
disrupt the site of initiation of transcription.  The healing of wounded skin of 
Jdp2KO mice proceeded more rapidly than that of control mice and more 
proliferating cells were found at wound margins.  Fibroblasts derived from 
embryos of Jdp2KO mice proliferated more rapidly and formed more colonies 
than wild-type fibroblasts.  JDP2 was recruited to the promoter of the gene for 
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cyclin A2 (ccna2) at a previously unidentified AP-1 site.  Cells lacking Jdp2 had 
elevated levels of cyclin A2 mRNA.  Moreover, reintroduction of JDP2 resulted in 
repression of transcription of ccna2 and of cell cycle progression.  Thus, 
transcription of the gene for cyclin A2 appears to be a direct target of JDP2 in the 
suppression of cell proliferation.  
 
Key words: cyclin A2/Jdp2 knock-out mice/cell proliferation/JDP2/skin wound 
healing/cell cycle arrest 
 
The abbreviations used are: AP-1, activation protein-1; BrdU, bromodeoxyuridine; 
ChIP, chromatin immunoprecipitation; CRE, cAMP-responsive element; DRE, 
differentiation response element; EMSA, electrophoretic migration shift assay; GPDH, 
glycerol 3-phosphate dehydrogenase; JDP2, Jun dimerization protein 2; KO, knock out; 
MEF, mouse embryonic fibroblast; NE, nuclear extracts. 
 
Introduction 
Progression of the cell cycle in mammalian cells is regulated by the interplay of protein 
kinase complexes, known as cyclin-dependent kinases (CDKs), that are controlled by 
the levels of expression of their respective cyclin partners, which act as positive 
coactivators or as negative regulators in the case of the so-called cdk inhibitors (Grana 
and Reddy, 1995; Sherr and Roberts, 1999; Malumbress and Barbacid, 2009). While 
cyclin D-cdk4/cdk6 and cyclin E-cdk2 control progression through G1 phase (Sherr, 
1993) and cyclin B-cdc2 appear to be necessary for entry into mitosis (Furuno et al., 
1999), cyclin A is a rate-limiting component required for both the initiation of DNA 
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synthesis and entry into mitosis (Pagano et al., 1992). There are two subtypes of cyclin 
A: cyclin A2, which is expressed almost ubiquitously, and cyclin A1, whose expression 
is restricted to the testis (Sweeney et al., 1996). In conditional cyclin A knock-out mice, 
the functions of cyclin A were essential for progression of hematopoietic cells and 
embryonic stem cells through the cell cycle but cyclin A is redundant in fibroblasts 
(Kalaszczynska et al., 2009). Expression of cyclin A is cell cycle-dependent with 
periodic relief of transcriptional repression.   
Jun dimerization protein 2 (JDP2), a member of the AP-1 family, is able to form 
homodimers, and, also, heterodimers with other members of the AP-1 family, such as c-
Jun, JunB, JunD and ATF2, and with a member of the C/EBP family, C/EBPγ 
(Aronheim et al., 1997; Jin et al., 2001; Broder et al., 1998). Assays involving ectopic 
expression of JDP2 indicated that JDP2 can block transformation of NIH3T3 cells and 
of lines of prostate cancer cells (Heinrich et al., 2004), whereas it also induces the 
partial transformation of chick embryonic fibroblasts (Blazek et al., 2003) and functions 
as a cell-survival protein in several cell lines (Lerdrup et al., 2005; Piu et al., 2001).  
JDP2 inhibits the differentiation of embryonal carcinoma F9 cells (Jin et al., 2002) and 
adipocytes (Nakade et al., 2007) and even promotes the differentiation of osteoclasts 
(Kawaida et al., 2003), C2 myoblasts and rhabdomyosarcoma cells (Ostrovsky et al., 
2002). JDP2 is expressed ubiquitously and its level does not change significantly after 
diverse forms of cellular stimulations. In this regards, it seems to be quite distinct from 
other major AP-1 proteins, which are generally regulated by a variety of stresses at 
several levels, such as expression, stability, dimerization with other factors and DNA-
binding activity.                                                                                                                                 
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JDP2 most likely participates in the repression of transcription via multiple 
mechanisms, which include DNA-binding competition and inactivation of formation of 
heterodimer with other members of the AP-1 (Aronheim et al., 1997), recruitment of 
HDAC 3 (Jin et al., 2002), inhibition of histone acetylation and the direct regulation of 
chromatin assembly (Jin et al., 2006). However, the details of the physiological role of 
JDP2 in cell fate remain unknown, and the mechanisms by which JDP2 acts as a 
regulator of the proliferation or transformation of cells remain to be clarified. Recently, 
we generated Jdp2-deficient mice, with a deletion in the promoter and non-coding exon 
1 region of the Jdp2 locus (Jdp2KO mice) and reported that “knock-out” of Jdp2 affects 
adipocyte differentiation (Nakade et al., 2007) and resistance to replicative senescence 
(Nakade et al., 2009).   
Although our Jdp2KO mice did not exhibit any apparent abnormalities under 
standard breeding conditions, we report here that loss of JDP2 results in accelerated cell 
cycling by embryonic fibroblasts (MEFs) and enhances the expression of cyclin A2 
through loss of direct binding to the promoter of the gene for cyclin A at a previously 
unidentified AP-1 motif. We also observed that the accelerated cell growth in the 
healing of skin wounds in adult Jdp2KO mice. Our data indicate that the gene for cyclin 
A is a direct transcriptional target of JDP2 in the repression of cell proliferation by 
JDP2. 
 
Materials and methods 
Plasmid construction, electophoretic mobility shift assays (EMSA), 
immunopreciptation and IP-Western blotting (see in the supplementary methods) 
Cell culture   
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Mouse embryonic fibroblasts (MEFs) were prepared from embryos at embryonic day 
12.5 (E12.5) with a mixed genetic background of B6 and 129 as described elsewhere 
(Nakade et al., 2007). For serum-starvation experiments, MEFs were incubated in 
DMEM that contained 0.1% FCS for 48 h, at confluence; then they were re-plated in 
DMEM that contained 15% FCS.   
Skin wound-healing model and scratch-wounding assay in vitro 
Jdp2KO male mice at 20-30 weeks of age (body weight, 30.3 ± 0.7 g) were used in skin 
wound-healing assays, together with sex- and age-matched WT littermates (body weight, 
29.5 ± 2.40 g). After shaving the dorsal hair and cleaning the exposed skin with 70% 
ethanol, we made full-thickness excision skin wounds aseptically unit a 4-mm biopsy 
punch. Each wound region was photographed digitally with a scale marker 1, 3, 6 and 9-
11 days after wounding. The size of the unclosed wound bed was calculated with the 
Image J program (version 1.36b; NIH, USA). Wounded mice were injected 
intraperitoneally with 20 µl/g body weight of bromodeoxyuridine (BrdU) labeling 
reagent (Roche Applied Science, Penzberg, Germany) on various days after wounding 
and killed 2.5 h after injection. Paraffin-embedded sections were subjected to 
hematoxylin-eosin staining and immunostaining with the BrdU Labeling and Detection 
Kit I (Roche Applied Science). The endothelial cells and fibroblasts that had 
incorporated BrdU at wound margins were photographed under a fluorescence 
microscope with a digital camera system (Olympus, Tokyo, Japan). The scratch-
wounding assay in vitro was performed with MEFs to mimic wound healing in 
individual mice. Confluent monolayer of cells were then scratched linearly and 
incubated for a few days in DMEM plus 15% FCS.  Photographs were taken 12 to 60 h 
after scratching. 
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Analysis of cell proliferation and the cell cycle  
MEFs were cultured at 5 x 105 cells per 10-cm dish or 2 x 104 cells per well in 24-well 
plates, in triplicate, to estimate proliferation rates. Cells were counted by the trypan blue 
dye-exclusion test (Gibco-Invitrogen) or after application of the Alamar Blue reagent 
(Alamar Biosciences, Sacramento, CA, USA) according to the manufacturers’ 
instructions. For analysis of the cell cycle, serum-starved MEFs were further cultured in 
DMEM that contained 15% FCS and collected at the indicated times.  Harvested cells 
were stained with propidium iodide (PI; 1 µg/ml), and subjected to fluorescence-
activated analysis of DNA content in a flow cytometer EPICS XL-MCL; Beckman 
Coulter, Miami, FL, USA). Percentages of cells at each phase of the cell cycle were 
determined. To count cells that had entered the S-phase from the G1-or G0-phase at 
higher sensitivity, we performed a BrdU-incorporation assay in vitro with the BrdU 
Labeling and Detection Kit I. Serum-starved MEF were seeded at 1 x 105 cells per 
chamber on chamber slides in DMEM plus 15% FCS. After 12 h, cells were pulse-
labeled for 3 h with 10 µM BrdU and the BrdU incorporated into cells was detected by 
immunocytochemical staining with antibodies against BrdU and fluoresceine-
conjugated second antibodies, together with staining with PI for localization of nuclei.  
For the colony-formation assay, MEFs were plated in duplicate at 5 x 102 or 5 x 103 
cells per 10-cm gelatin-coated dish. After two weeks, colonies with diameters greater 
than 2 mm were counted after staining with Giemsa staining solution (Wako Chemicals, 
Co., Tokyo, Japan). 
Isolation of RNA, microarrays and real-time quantitative RT-PCR 
Total RNA was extracted from various tissues of both Jdp2KO and WT adult mice, 
from embryos and from corresponding MEFs with Trizol (Invitrogen) according to the 
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manufacturer’s instructions. Expression of JDP2 mRNA was analyzed by Northern 
blotting as described elsewhere (Jin et al., 2002). For microarray analysis, total RNA (5 
µg) was converted to cRNA with aminoallyl-UTP and fluorescence-labeled with a low-
input RNA linear amplification kit (Agilent Technologies, Inc., Santa Clara, CA USA) 
and Cy3- or Cy5-labeled CTP (PerkinElmer, Waltham, MA, USA). Samples of Cy3-
labeled WT RNA and Cy5-labeled JDP2-deficient RNA (750 ng) were combined in 
equal amounts and allows to hybridize to a microarray (Agilent Mouse Oligonucleotide 
Array, 22,000 features, Agilent Technologies Inc.) for 17 h at 60 °C, with subsequent 
washing, drying and storage under nitrogen in darkness. Hybridization signals recorded 
with a microarray scanner (Agilent) were normalized and corrected for background 
signals (with Agilent Feature-Extraction software). Real-time quantitative RT-PCR 
(qRT-PCR) was performed with a PRISM™ 7700 system (Amersham Biosystems 
Instruments, Foster City, CA, USA) according to the manufacturer’s instructions. We 
designed the primers using the public-domain Primer 3 program of GENETYX-Mac 
Ver.14 software (Hitachi Software, Tokyo, Japan). The respective pairs of primers were 
listed in Supplementary Table 2.    
Promoter reporter assays 
Cyclin A2 promoter-reporter DNAs were transfected into WT and Jdp2KO MEFs with 
or without pcDNA3-JDP2 or pcDNA3 empty vector at 1 µg of total DNA per well of a 
24-well plate (5 × 104 cells/well) using 2 µl of LipofectamineTM-2000 reagent 
(Invitrogen). A series of JDP2 promoter-reporters were transfected in a similar way as 
described elsewhere (Jin et al., 2002; Nakade et al., 2006).  
Assay of cyclin A2-associated kinase activity 
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We immunoprecipitated total cellular proteins with antibodies against cyclin A2 and 
protein A-Sepharose beads. The beads with bound immune complexes were mixed with 
[32P]-ATP and histone H1 peptide substrate (cat. no. 14-155; Upstate biotechnology 
Co.) in a kinase assay buffer [50 mM HEPES (pH 7.0), 10 mM MgCl2, and 1 mM 
dithiothreitol) for 30 min at 30 °C. Reaction products were resolved by SDS-PAGE 
(12% polyacrylamide) and phosphorylated histone H1 peptide was detected by 
autoradiography. 
Adenoviral infection 
Replication-defective adenovirus that encoded JDP2 (Ad-JDP2) and β-galactosidase 
(Ad-cont) were generated from pAxCAwt, as described elsewhere (RIKEN DNA Bank; 
Miyake et al., 1996, Ugai et al., 2005).  
siRNA transfection 
4 x 104 WT and Jdp2KO MEFs at 60% confluence were transfected with 20 pmole of 
control siRNA (Invitrogen 45-2002; lot 360646) and two siRNAs (#1 and #2; Nakade et 
al., 2009) against JDP2 according to the manufacturer’s instruction (Amgene and 
Invitorgen, respectively).   
Analysis of data 
Results are expressed as the mean plus or minus the standard deviation (± SD) of results 
for each set of replicates. Statistical comparison of single parameters between two 
groups was performed by a paired Student t-test.  P values of less than 0.05 or 0.01 were 
considered significant. 
 
Results 
Assays of skin-wound healing and scratch wounding 
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To investigate the functional impact of loss of expression of the Jdp2 in vivo, we used a 
model of skin-wound healing to compare the healing of skin between WT and Jdp2KO 
mice. Male C57/BL6J mice were injured by excising full-thickness skin (a disk of 4 mm 
in diameter) from their shaved backs. In control WT mice, re-epithelialization was 
complete within 11 to 13 days after injury. In the case of Jdp2KO mice, the skin seemed 
to re-epithelialize rapidly within 10 to 11 days. Recovery of skin wounds was examined 
by macroscopic observation of the wounded skin on days 1, 3, 6 and 10 after injury 
(Figure 1A). We measured the area of the wound in each case and found that wound 
repair was accelerated in Jdp2KO mice (Figure 1B). In order to compare the 
proliferative potential of cells after tissue injury in Jdp2KO and WT mice, we labeled 
wound mice with bromodeoxyuridine (BrdU) in vivo. Wounded mice were injected 
intraperitoneally with BrdU at 0, 1, 3 and 6 days after wounding and sacrificed 2.5 h 
after injection. Samples of skin wounds were excised for the preparation of paraffin-
embedded sections, which were subjected to immunostaining with antibodies against 
BrdU (Figure 1C). We found large numbers of BrdU-positive endothelial cells and 
fibroblasts at wound margins, and the numbers of BrdU-positive cells at wound margins 
in Jdp2KO mice were 2- to 5-fold higher than in WT mice. Thus, enhancement of cell 
proliferation in Jdp2KO mice apparently contributed to enhanced repair of wounds. 
Levels of mRNAs for PCNA, Col1a1 and cyclin A2 were higher in the skin of Jdp2KO 
mice than in that of WT mice 1, 3 and 6 days after injury (Figure 1D). Thus, JDP2 was 
clearly involved in the expression of growth-related genes, such as those for PCNA, 
Col1a1 and cyclin A2.   
We performed wound-scratch assays in vitro with mouse embryonic fibroblasts 
(MEFs) that mimic the phenomenon of wound healing in intact mice. The rate of 
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migration into the scratch of Jdp2KO MEFs was 1.4-fold higher than that of WT MEF 
(Figure 1E). At 36 h, the wounded area had disappeared in the case of MEFs from 
Jdp2KO mice but not from WT MEFs (data not shown). The rate of migration into the 
scratch of Jdp2KO MEFs was 1.4-fold higher than that of WT MEF. These data indicate 
that the JDP2 is involved in the suppression of cell proliferation in WT MEF. 
Control of the proliferation of Jdp2-deficient cells 
We prepared MEFs from Jdp2KO embryos on day 12.5 post coitus.  Northern blotting 
analysis both of embryos and of isolated MEFs failed to reveal any JDP2 mRNA when 
we used a DNA probe from the Jdp2 coding region (Figure 2A) and when we used a 
DNA probe that corresponded to the 3’ non-coding region (data not shown). Thus, 
expression of JDP2 mRNA had been completely disrupted in embryos and MEFs from 
Jdp2KO mice. Controls from WT embryos yielded the expected size of JDP2 mRNA. 
We next performed Western blotting analysis of lysates of MEFs from WT and 
Jdp2KO mice using antibodies against JDP2 (a gift from Dr. A. Aronheim; Figure 2B).   
Bands specific for JDP2 (18.5 kDa) were detected in the analysis of WT MEFs but not 
in that of Jdp2KO MEFs in both assays with the different JDP2-specific antibodies.   
 In our analysis of cell proliferation, we examined the proliferation of MEF using 
three different assays, namely, trypan blue dye-exclusion, the Alamar Blue assay, and 
colony formation. Figure 2C shows that Jdp2KO MEFs proliferated more rapidly than 
WT MEFs when plated at 5 x 105 cells per 10-cm dish in DMEM plus 10% FCS. The 
results of the cell growth assay with Alamar Blue dye also supported this conclusion 
(Figure 2D).  The colony-formation assay also confirmed this result. We plated 5 x 102 
cells and 5 x 103 cells in gelatin-coated 10-cm dishes and counted colonies (of more 
than 2 mm in diameter) after two weeks. The Jdp2KO MEFs were able to form colonies 
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more efficiently than the WT MEFs (Figure 2E). These results indicated that JDP2 plays 
a critical role in growth control both in vitro and in vivo. 
Absence of a requirement for JDP2 in apoptosis induced by UV and DNA-
damaging reagents 
Piu et al. (2001) reported that JDP2 plays a critical role in UV-induced apoptosis.  
However, evidence for such a role was only provided by results of experiments that 
involved over-expression of JDP2 in specific cell lines. We found that UV-irradiated 
MEFs underwent apoptosis in a dose- dependent manner at doses of UVC from 20 to 60 
J/m2, but we did not detect any obvious difference between WT and Jdp2KO MEFs in 
subsequent trypan blue dye-exclusion assays (Supplementary Figure 3A) and assays of 
the activities of caspases 3 and 7 (Supplementary Figure 3B). When MEFs were 
exposed to UVC at 60 and 600 J/m2, for 2 h and 8 h, the level of expression of JDP2 fell 
significantly (Supplementary Figure 3D). We also irradiated MEFs with UVC at 20 
J/m2, incubated them for another 24 h, and then subjected them to flow cytometry to 
assess levels of sub-G1 cells. The size of the sub-G1 population of UV-irradiated MEFs 
from Jdp2KO mice was identical to that of MEFs from WT mice (Supplementary data 
3C). We also examined the effects of a set of chemical inducers of apoptosis.  We 
exposed MEF to various inducers of apoptosis, such as actinomycin D (10 μM), 
camptothecin (2 μM), cycloheximide (100 μM), dexamethasone (100 μM), and 
etoposide (100 μM) for 24 h. All reagents induced increases in the activities of caspases 
3 and 7 in a dose-dependent manner (data not shown), but no significant differences in 
respective activities were found between WT and Jdp2KO MEFs (Supplementary 
Figure 4) except after the application of cycloheximide, an inhibitor of protein 
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synthesis.  These data suggested that JDP2 has no significant effect on the apoptotic 
responses to UV and inducers of cell death in normal MEFs. 
We next performed a cell cycle re-entry assay, counting propidium iodide-stained 
(PI-stained) MEFs by flow cytometry.  MEFs cultured in serum-free medium were re-
stimulated by addition of 15% FCS and then harvested at various time after the addition 
of FCS. One representative experiment showed that 28% of Jdp2KO MEFs were in the 
S-phase, while only 20% of WT MEFs were in the S-phase after 18 h of stimulation 
(Figure 3A). The number of MEFs derived from Jdp2KO mice in the S-phase was 
considerably higher than that of WT MEFs (Figure 3B). Proliferation of Jdp2KO MEFs 
was accelerated as a result of enhanced progression of cells from the G1- or the G0-
phase to the S-phase, and not as a result of differential activity related to cell death.  
We also examined the incorporation of BrdU into MEFs. Serum-starved MEFs 
were seeded in chamber slides at a given density in DMEM plus 15% FCS. After 
incubation for 12 h, cells were pulse-labeled with 10 µM BrdU for 3 h. Cells in S-phase 
that had incorporated BrdU were detected with antibodies against BrdU and fluorescein-
conjugated second antibodies (Figure 3C). The percentages of BrdU-positive cells in six 
areas of chambers demonstrated that Jdp2KO MEFs moved more frequently from a 
quiescent state to a proliferative state than did WT MEFs (Figure 3D). 
Regulation of cell cycle-related genes by JDP2 
To examine the role of JDP2 in the cell cycle, we analyzed the expression of individual 
cell cycle-related genes. MEFs were arrested at the G0/G1-phase by deprivation of 
serum for 48 h, and then re-entry into cell cycle was triggered by re-plating in DMEM 
plus 15% FCS. As shown in Figure 4A, no notable differences in levels of proteins, 
such as cyclin D1, cyclin D3, cdk4, cdk6 and Rb were detected between WT and 
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Jdp2KO MEFs.  Levels of p53 and p21 in Jdp2KO MEFs were lower than those in WT 
MEFs after induction by serum (Figure 4A).  
We next examined global gene expression in Jdp2KO MEFs using an oligo DNA 
microarray from Agilent Technologies, Inc. (Santa Clara, CA, USA), known as 
“Mouse”. We extracted total RNA from WT MEFs and from Jdp2KO MEFs, which had 
been synchronized by serum-starvation for 48 h and then stimulated with 15% FCS in 
DMEM for 14 h. The genes identified included up- or down-regulated genes, genes for 
cyclins and p53-related genes, as listed in Figure 4C and the entire data set from the 
microarray analysis is available at the CIBEX database (CIBEX, Mishima, Japan; 
CIBEX accession, CBX101).  Elevated expression of genes for cyclin A2 and cyclin E2 
was detected in Jdp2KO MEFs as compared to WT MEFs. Conversely, genes for the 
cyclin-dependent kinase inhibitor p21, p16 and p15, but not for p27, were expressed at 
lower levels in Jdp2KO MEFs than in WT MEFs. Genes from families of apoptosis-
related genes and genes for other AP-1 and C/EBPs did not reveal any remarkable 
differences between Jdp2KO and WT MEFs, exception in the case of JDP2 and C/EBPδ. 
Expression of 21 known genes differences between Jdp2KO and WT MEF, was 
enhanced and that of 20 known genes was depressed in Jdp2KO MEFs (Supplementary 
Table 1).   
We performed two microarray assays and each assay revealed the increased 
expression of genes for cyclin A2 and cyclin E2 and the decreased expression of genes 
for p21, p16 and p15 in Jdp2KO MEFs. Moreover, as shown in Figure 4B, the 
correlation coefficient with respect to the relative changes in levels of mRNAs between 
the two assays was higher than 0.8, indicating that the data from the microarrays were 
valid. 
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We compared the levels of expression of mRNAs in WT MEFs and Jdp2KO MEFs 
by real time RT-PCR, respectively, before and after re-stimulation with serum. We 
examined the levels of the transcripts of representative genes, which appeared to have 
risen or fallen in microarray studies, as well as those of members of the AP-1/ATF 
family, including c-Jun, c-Fos and JunD. The results were consistent with those in the 
microarray assay (Figures 4C and 4D). 
Cyclin A2 is a target of JDP2 
Our microarray study indicated that JDP2 might be involved in the negative regulation 
of progression of the cell cycle via regulation of the expression of the gene for cyclin 
A2 (ccna2). We examined the level of cyclin A2 mRNA by real-time PCR after re-
stimulation of MEF by serum. The expression of cyclin A2 was enhanced by addition of 
FCS in both lines of MEFs. However, a more significant increase (1.5- to 2.0-fold) in 
the expression of cyclin A2 was noted in Jdp2KO MEFs than in WT MEFs after 
stimulation. In parallel, we also measured the kinetics of changes in levels of mRNA for 
JDP2 and c-fos (Figure 5A). The expression of JDP2 mRNA decreased slightly after 
serum stimulation in WT MEF. By contrast, expression of c-fos mRNA rose rapidly but 
transiently within 4 h after the start of stimulation, without any significant difference 
between the two lines of MEFs. As shown in Figure 5B, levels of mRNAs for cyclin A2 
and cyclin E2 were significantly higher and expressions of both genes started earlier in 
Jdp2KO MEFs than in WT MEFs after the re-addition of serum. By contrast, expression 
of the cell cycle inhibitor p16Ink4a decreased gradually for the first 6 h after the start of 
stimulation with FCS only in Jdp2KO MEFs. The expression of p21 mRNA remained 
almost unchanged in both lines of MEFs. 
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We performed a chromatin immunoprecipitation (ChIP) assay to investigate 
whether or not JDP2 regulates the expression of its target genes directly. 
Immunoprecipitated proteins with monoclonal antibodies against JDP2 (#176) were 
applied to PCR for detection of promoter target regions of genes for cyclin A2, cyclin 
E2, and p16Ink4a, respectively.  We detected products of PCR that corresponded to the 
promoter regions of genes for cyclin A2 and p16Ink4a in the sonicated chromatin derived 
from WT MEFs but not from Jdp2KO MEFs (Figure 5C). In the case of cyclin E2, no 
specific band was detected and only faint bands appeared after amplification for 45 
cycles, even when we used JDP2- deficient cells. Our data indicated that genes for 
cyclin A2 and p16Ink4a are the most likely targets of JDP2 in progression of the cell 
cycle, even though they exhibited opposite responses upon serum stimulation of serum-
starved cells. After the addition of FCS, JDP2 appeared to be recruited to the 
transcriptional regulatory region of the gene for cyclin A2 and to be released from the 
p16Ink4a locus.   
Promoter analysis of the gene for cyclin A2  
We cloned a 1,101-bp fragment of DNA from the 5’ region of the mouse gene for cyclin 
A2 and constructed a series of promoter deletion-luciferase genes (Figure 6A). We 
deteted 2.5- to 4.5-fold higher luciferase activity in Jdp2KO MEFs than in WT MEFs 
when we tested this series of deletion constructs, even though the activities due to the 
control reporter vector, with an SV40 promoter, were identical in both lines of MEFs 
(Figures 6B and 6D). Moreover, deletion of the SacI-XhoI fragment that contained the 
AP-1 site increased luciferase activity in WT MEFs but not in Jdp2KO MEFs, 
suggesting that the region from SacI to XhoI is important for JDP2-mediated repression 
of the expression of cyclin A2. A point mutation at the AP-1 site enhanced luciferase 
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activity in WT MEFs but not in Jdp2KO MEFs (Figure 6C). By contrast, a point 
mutation at the CRE or at both the AP-1 site and the CRE resulted in decreased 
luciferase activities in both lines of MEFs, indicating that the CRE has cis-activity in the 
cyclin A2 promoter that is under the control of CRE-binding activators, even though 
JDP2 might still be a repressive component in the activation complex. When we 
transfected cells with reporter constructs p3AP1 and p3CRE, in which a 3x AP-1 
consensus sequence or a 3x CRE consensus sequence had been inserted in the TK-
luciferase vector (Promega), the luciferase activities due to these constructs were higher 
in Jdp2KO MEFs than in WT MEFs (data not shown), supporting the definition of 
JDP2 as an AP-1/CRE-dependent repressor in MEF (Aronheim et al., 1997; Jin et al., 
2002).   
To determine whether JDP2 represses the expression of the gene for cyclin A by 
exploiting its histone-modification activity, as described previously (Jin et al., 2006), 
we performed ChIP assays with antibodies against acetyl-H4 to assess the histone-
acetylation status of the promoter region of the gene for cyclin A in WT and Jdp2KO 
MEFs. The level of actylation of histone H4 in Jdp2KO MEFs was clearly higher than 
that in WT MEFs (Supplementary Figure 5).   
 Binding of JDP2 to the cyclin A2 promoter 
We performed electrophoretic mobility shift assays (EMSAs) to verify the DNA-
binding activity of JDP2 using oligodeoxynucleotide probes that corresponded to the 
AP-1 site, the CRE and the AP-1-like site, as a control. As shown in Figure 7A, the AP-
1 and CRE probes but not the AP-1-like probe generated large DNA-protein complexes 
with nuclear extracts from either WT MEFs or Jdp2KO MEFs (lanes 2 and 3 for CRE; 
and lanes 8, 9 and 11 for AP-1). The corresponding unlabeled competitors released 
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[32P]-radiolabeled-oligodeoxynucleotides from the DNA-protein complexes (compare 
lanes 13 to 15 with lane 11), but less effective competition was observed with an AP-1 
mutant oligodeoxynucleotide (lane 12). When we added antibodies specific for JDP2 
(#249) to the reaction mixture with the AP-1 probe, we detected super-shifted bands in 
the case of nuclear extracts from WT MEFs but not from Jdp2KO MEFs (compare lane 
2 with lane 4 and lane 6 with lane 8 in Figure 7B).  Moreover, the band in the case of 
serum-stimulated WT MEFs was less intense than that from serum-starved WT MEFs, 
indicating that addition of FCS suppressed the formation of a protein-DNA complex 
that included JDP2 under these conditions. By contrast, the CRE oligodoxynucleotide-
protein complex was shifted by addition of antibodies specific for JunD but not by 
antibodies specific for JDP2 (Figure 7C), indicating that the CRE site “preferred” 
members of the AP-1 family other than JDP2.  These data strongly suggest that JDP2 
binds to the AP-1 site of the promoter of the gene for cyclin A2 and the induction of 
progression of the cell cycle with serum suppressed formation of the JDP2-DNA 
complex.    
Elevated levels of the cyclin A2/cdk2 complex and of cdk activity in Jdp2KO cells  
We detected cyclin A2 by Western blotting of lysates of MEFs prepared at various time 
after re-stimulation with FCS. The level of cyclin A2 was 3-to 5-fold higher in Jdp2KO 
MEFs than in WT MEFs, irrespective of whether the source of extracts was whole cells 
or nuclei (Figure 8A). We immunoprecipitated cdk2 with antibodies against cdk2 from 
equal amounts (as 400 μg protein) of cell lysate prepared from WT and Jdp2KO MEFs 
0, 8, 16 and 20 h after re-addition of FCS. Immunoblotting with antibodies specific for 
cyclin A and cdk2, and for β-actin as a control, revealed that the amount of cyclin A 
associated with cdk2 was dramatically increased by serum stimulation, even though the 
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level of cdk2 was almost constant. Moreover, the level of the cyclin A/cdk2 complex in 
Jdp2KO MEFs was 2-to 3-fold higher than in WT MEFs, with the difference being 
especially marked 16 to 20 h after the re-addition of FCS (Figure 8B) 
In an attempt to measure levels of cyclin A2-associated kinases, such as cdk2, we 
prepared lysates from WT and Jdp2KO MEFs and subjected them to 
immunoprecipitation with antibodies against cyclin A2. Then we mixed immune 
complexes with [γ32P]-ATP and histone H1 peptide as a substrate in a kinase assay 
buffer. The resultant phosphorylated H1 peptide was detected by SDS-PAGE and 
autoradiography (Figure 8C). We found that lysates from Jdp2KO MEFs had several-
fold-higher kinase activity than those from WT MEFs (based on the radioactivity).  
Repression by JDP2 of cell growth and the reporter activity of the cyclin A2 
promoter   
We examined the effects of JDP2 on the proliferation of MEF by over-expressing JDP2 
in WT MEFs and re-expressing JDP2 in Jdp2KO MEFs. First, we introduced a JDP2 
expression vector into WT and Jdp2KO MEFs and we monitored cell numbers with 
Alamar Blue three days after transfection (2- to 3-fold increase of JDP2 mRNA 
expression; data not shown). As shown in Figure 9A, the JDP2 expression vector 
suppressed cell growth in both lines of MEFs, and the effects in Jdp2KO MEFs were 
more significant than in WT MEFs. 
We used the cyclin A2 promoter-reporter construct pA2M and the corresponding 
construct with a mutation at the AP-1 site to examine the effect of re-expression of 
JDP2 in Jdp2KO MEFs. Transfection with pcDNA-JDP2 reduced the reporter luciferase 
activity significantly in the case of pA2M, but not in the case of the mutant reporter 
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pA2mAP1 (Figure 9B). These data suggested, yet again, that JDP2 represses the activity 
of the cyclin A2 promoter, in a manner dependent specifically on the AP-1 site.  
When we used a recombinant adenovirus vector that encoded JDP2 to induce its 
over-expression, infection with the JDP2-expressing virus significantly suppressed cell 
growth in both WT and Jdp2KO MEFs, acting in a dose-dependent manner, even at an 
m.o.i. of 1 (Ad JDP2 increases 50- to100-fold expression of JDP2, Nakade et al., 2009).  
The expressed JDP2 almost halved the number of WT and Jdp2KO MEFs on day 5 
(Figure 9C). Moreover, expression of cyclin A2 was significantly depressed in both 
lines of MEFs (Figure 9D). Thus, ectopic expression of JDP2 appeared to suppress the 
proliferation of MEFs by regulating the expression of cyclin A2.  
We also examined the effects of JDP2-specific siRNAs on the proliferation of 
MEFs.  In WT MEFs, two different JDP2-siRNA constructs reduced the expression 
level of JDP2 by as much as 50% (Figure 9F). These siRNAs accelerated the 
proliferation of WT MEFs but not of Jdp2KO MEFs (Figure 9E). Moreover treatment 
with JDP2-siRNA of WT MEFs increased the level of cyclin A2 mRNA but reduced the 
level of cyclin A2 mRNA in Jdp2KO MEFs (Figure 9F). These data strongly suggest 
that JDP2 represses progression of the cell cycle via the expression of cyclin A2, 
thereby inhibiting the proliferation of mouse MEFs. 
 
Discussion 
In the present study we demonstrated that loss of JDP2 allows the enhanced expression 
of cyclin A2, which stimulates the proliferation of mouse skin and embryonic 
fibroblasts (MEFs).  Wounds in the skin of Jdp2KO mice healed more rapidly than 
those in the skin of WT mice (Figures 1A and 1B), with larger numbers of proliferating 
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cells at the wound margins in Jdp2KO mice (Figure 1C). Incorporation in vivo of BrdU 
into DNA in skin from Jdp2KO mice was more than 1.8-fold higher than that in skin 
from WT mice. The scratch-wounding assay of MEFs in vitro also showed the same 
conclusion (Figure 1E). These activities are indicated as the proliferation capacity of 
cells. The cell proliferative activity of Jdp2KO MEFs was much higher than that of WT 
MEFs (Figure 2D), no matter what the number of passages (Figure 2C), as was the rate 
of formation of foci (Figure 2E). Moreover, more cells had entered S-phase in cultures 
of Jdp2KO MEFs than in those of WT MEFs 18 h after serum induction (28% vs 20% 
in Figure 3A) and approximately 3.7-fold more of BrdU-incorporating cells were 
detected (Figure 3C). Taken together, these different assays revealed the elevated 
proliferative potential of MEFs from Jdp2KO, as compared to WT MEFs and 
furthermore, JDP2 does not affect apoptosis but controls proliferation, at least in normal 
cells (Supplementary Figure 3). 
To identify the target gene of JDP2, we used a mouse microarray to identify 
changes in levels of transcripts of genes related to the cell cycle, of genes for some 
growth factors and of genes for some AP-1/ATF transcription factors in Jdp2KO MEFs. 
After serum induction, the level of cyclin A2 mRNA rose 2- to 3-fold in Jdp2KO MEF, 
as compared with that of WT MEFs (Figures 5A and 5B). We examined the promoter of 
the gene for cyclin A2 in terms of DNA-binding proteins and specific binding sites.  
The effects of mutation of the AP-1 site were clear in WT MEFs but not in Jdp2KO 
MEFs. By contrast, mutation of the CRE resulted in lower activity in both line of MEFs 
(Figure 6C). A gel shift assay demonstrated that no proteins bound to the far-upstream 
AP-1-like site, while the AP-1 site and CRE recruited specific proteins to form DNA-
protein complexes (Figure 7A). In the case of the AP-1 site, JDP2 was included in the 
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shifted DNA-protein complex, but no shifted band was detected in the case of nuclear 
extracts of Jdp2KO MEFs. When WT MEFs were stimulated with serum, the intensity 
of the shifted band that included JDP2 decreased significantly (compare lanes 2 and 6 in 
Figure 7B). In the case of cyclin E2, the level of mRNA fell transiently from 3 to 8 h 
after addition of serum and then gradually returned to its initial level (Figure 5B).  
However, no AP-1/CRE elements have been found in the promoter region of the gene 
for cyclin E2.  Thus, regulation of transcription of cyclin E2 might be other mechanism 
like histone modification (Jin et al, 2006; nakade et al, 2009) or translational regulation 
of cyclin E2 (Mullany et al, 2007).  
Previous studies demonstrated that JunB binds to the CRE at S-phase (Andrecht et 
al., 2002). ChIP assays also demonstrated that JunB binds to this CRE in ras-
transformed rat thyroid cells in G2 (Casaline et al., 2007), as confirmed subsequently in 
exponentially growing HeLa cells (Farras et al., 2008). Farras et al. (2008) also 
demonstrated that the AP-1 site can bind JunB- and Fra-1-containing AP-1 dimers more 
efficiently than the CRE. In ras-transformed cells, levels of both Fra-1 and JunB are 
dramatically higher than in the normal cell counterparts (Casalino et al., 2003; 
Piechaczyk and Farras, 2008). However, in our present study, we found that JunD and 
c-Fos, and not JunB and Fra-1, bound to the CRE in mouse WT MEFs. Thus, the 
composition of the AP-1 complex might differ among cell types, playing a critical role 
in the expression of cyclin A2 to promote progression of the cell cycle. We found that 
JDP2 is recruited only to the AP-1 site of the cyclin A2 promoter for negative regulation 
of transcription.  
It remains to be determined whether the AP-1 site is functional or not.  The present 
study demonstrated, first, that the AP-1 site is critical for the repression of the cyclin A2 
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promoter by JDP2. We also demonstrated that cyclcin A2 associates with cdk2 to 
exhibit cdk-kinase activity (Figure 8). The expression of cyclin A2 is elevated in Jdp2-
null cells and then cdk-kinase activity is enhanced, with promotion of cell proliferation. 
JunB-Expressing fibroblasts exhibit proliferative defects that are due to an extended 
G1-phase. The accumulation of JunB leads to cell-cycle arrest in G1 via induction of the 
expression of the gene for an inhibitor of a cell-cycle-related kinase, p16Ink4a (Passegue 
and Wagner, 2000). Moreover, overexpression of JunB antagonizes c-Jun-mediated 
induction of the expression of cyclin D1 in G2 (Bakiri et al., 2000). Cells are, 
consequently, blocked before they can enter S-phase, with possible subsequent 
senescence (Passegue and Wagner, 2000). The proposed anti-proliferative function of 
JunB is supported by the observation that JunB-null transgenic mice with a 
myeloproliferative disease progress to “blast crisis” (Passegue et al., 2001). The absence 
of JunB expression results in down-regulation of the expression of p16Ink4a and elevated 
levels of c-Jun (Passegue et al., 2001).    
In a similar way, we reported recently the down-regulation of p16Ink4a on 
Jdp2MEFs through the binding of JDP2 to histone (Nakade et al., 2009). In the present 
study, the level of p16Ink4a mRNA was reduced from 6 to 16 h after the start of serum 
induction, recovering again at 20 h (Figure 5B). The level of p16Ink4a was significantly 
lower in Jdp2KO MEFs than in WT MEFs, so we examined the recruitment of JDP2 to 
the promoter regions of genes for cyclin A2 and p16Ink4a (Nakade et al., 2009), as well 
as for cyclin E2 by ChIP assays. Our data strongly suggested that JDP2 was recruited to 
the promoters of genes for cyclin A2 and p16Ink4a, but not for cyclin E2 (Figure 5C).  
However, we do not know the exact role of JDP2 in the modification of histone at and 
near the AP-1 site of the cyclin A2 promoter. The polycomb like transcriptional 
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repressor Bmi-1 causes the increases in levels of p16Ink4a and greatly reduces the self-
renewal capacity of stem cells (Molofsky et al., 2003; Park et al., 2003). Sebastian et al. 
(2009) recently reported that overexpression of mixed-lineage leukemia 5 protein 
(MLL5; a trithorax homolog) indirectly regulates H3K4 methylation and represses 
expression of cyclin A2, with resultant promotion of myogenic differentiation. MLL5 
indirectly represses the ability of both LSD1 and Set7/9 to methylate H3K4. Although 
we do not yet know the details of possible molecular interactions between JDP2 and the 
MLL complex on the cyclin A2 promoter, Nakade et al. (2009) reported the interaction 
of JDP2 with histone H3K27, which prevented methylation through the polycomb 
complexes PRC1 and PRC2. It is possible that JDP2 might bind to histone H3K4 for 
regulation of the gene for cyclin A2. Moreover, we previously reported that JDP2 can 
inhibit histone acetylation by p300, in particular the acetylation of H3, H4K8 and 
H4K16 residues in vivo, as well as the nucleosome-assembly activity (Jin et al., 2006).  
Mateo et al. (2009) also showed that the degradation of cyclin A is regulated by 
acetylation mediated by P/CAF.  In fact, we found that JDP2 associated and colocalized 
with cyclin A in the nucleus by studies of cytochemistry (Supplementary Figure 6) and 
IP-Western blotting (data not shown). Therefore it is possible to JDP2 may regulate the 
stability of cyclin A2 through acetylation. Taken together, the repression of the 
expression of cyclin A2 is clearly due to the DNA-binding activity of JDP2 through AP-
1 site. Not only binding to DNA but also INHAT by JDP2 or control of cyclin A 
stability by JDP2 (data not shown) might play a critical role in the negative regulation 
of expression of the gene for cyclin A2. The molecular interaction studies of the role of 
JDP2 in mediating acetylation by P/CAF and degradation of cyclin A2 are in progress in 
our laboratory. 
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In summary, our data indicate that JDP2 plays a role in suppression of the 
expression of cyclin A2, with subsequent inhibition of the kinase activity of cyclin A2-
cdk2 and, finally, the suppression of cell proliferation. This hypothesis was supported 
by the results of overexpression of JDP2 encoded by a recombinant adenovirus and of 
gene-suppression experiments with siRNA (Figure 9). It is clear, moreover, that 
depletion of JDP2 interferes with progression of the cell cycle but not apoptosis. 
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Figure legends 
Figure 1 Proliferation of cells of WT and Jdp2KO mice during wound healing in vivo 
and scratch-wound healing in vitro. (A) Full-thickness excision wounds were made 
aseptically with a 4-mm biopsy punch on the skin of WT and Jdp2KO C57BL6 x 129 
mice and images of each wound are shown on days 1, 3, 6 and 10 after injury. (B) 
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Wound areas were calculated on days 3, 6 and 9 after injury. Mean values from three 
experiments are shown with standard deviations. (C) Skin was wounded as in (A) and 
then mice were injected intraperitoneally with 20 µl/g body weight of BrdU-labeling 
reagent (Roche) on days 1, 3 and 6 after wounding. Mice were sacrified 2.5 h after 
injection. Sections were stained with hematoxylin-eosin and immunostained with the 
BrdU labeling and detection kit (Roche). (D) Skin wounds and surrounding areas were 
excised with an 8-mm biopsy punch at the indicated times after injury. Total RNA was 
analysed by semi-quantitative RT-PCR with appropriate primers, as indicated on the 
right. (E) MEFs from WT and Jdp2KO mice were grown in DMEM and started of 
serum for 36 h. Confluent monolayers were scratched, and incubated in DMEM plus 
15% FCS for 12 h and then photographed.   
Figure 2 Proliferative properties of MEFs from WT and Jdp2KO mice. (A) The 
expression of JDP2 mRNA in embryos and in MEFs from WT and Jdp2KO mice was 
analyzed by Northern blotting. The blot was re-probed for analysis of GPDH mRNA as 
a loading control. (B) The expression of JDP2 in MEFs from WT and Jdp2KO mice 
was examined by Western blotting. (C) and (D) Proliferation of MEFs from WT and 
Jdp2KO mice. MEFs were cultured in 10-cm dishes with DMEM plus 10%FCS for 3 
days and then re-inoculated at the same density for ten passages. Cell numbers were 
determined at each passage (C).  In (D), MEFs were starved in DMEM plus 0.1% FCS 
for 36 h and then re-plated in DMEM plus 15% FCS and cultured for 5 days. MEFs 
were counted. (E) MEFs from WT and Jdp2KO mice were plated in gelatin-coated 
dishes. Colonies (of more than 2 mm in diameter) were counted two weeks later. 
Figure 3 Proliferation of MEFs from WT and Jdp2KO mice. (A) Serum-starved cells (5 
x 105) were cultured in DMEM plus 15% FCS for 18 h, stained with PI and subjected to 
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FACS analysis to determine the percentage of cells in each phase of the cell cycle. (B) 
The percentage of MEFs in the S-phase was determined after re-stimulation in the 15% 
FCS at 4-h intervals, as in (A). (C) MEFs were cultured in chamber slides in DMEM 
with 15% FCS for 12h and then pulse-labeled with 10 mM of BrdU for 3 h.  Labeled 
cells were detected by immunostaining with BrdU-specific antibodies.  Scale bars 
represents 100 μm. (D) Percentages of MEFs that were stained with BrdU-specific 
antibodies.  Means of results of three experiments are shown.    
Figure 4 Gene expression in WT and Jdp2KO MEFs, as determined by Western 
blotting, microarray analysis and real-time PCR. (A)Western blots of cell cycle-related 
proteins in MEFs from WT and Jdp2KO mice. MEFs were synchronized by serum 
starvation for 48 h and then re-stimulated with 15% FCS. MEFs were harvested 8 h, 12 
h and 16 h after the addition of serum and cell lysates were prepared. (B) Summary of 
the microarray data obtained with mRNA from WT and Jdp2KO MEFs.  (C) Validation 
of hybridization intensities. The correction coefficient with respect to relative changes 
in mRNA levels in two assays was higher than 0.8, indicating that the microarray data 
are valid. (D) Analysis by quantitative PCR of the expression of representative genes 
using mRNA from WT MEFs (gray lanes) and Jdp2KO MEFs (Black lanes). MEFs 
were harvested after serum induction for 3 h and 18 h and then real-time PCR was 
performed with primer sets for the indicated genes, as described in the text. The level of 
each respective mRNA in non-stimulated WT MEF was taken as 100.  
Figure 5 Kinetics of expression of cell cycle-related genes in WT and Jdp2KO MEFs.  
(A) Relative levels of expression of genes for cyclin A2, JDP2 and c-fos during cell 
cycling. Serum-starved MEFs from Jdp2KO (KO; black squares) and WT (black 
circles) mice were re-stimulated with serum for 24 h. The relative levels of respective 
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mRNAs, normalized by reference to GPDH mRNA, were compared at indicated times. 
(B) Western blots of products of cell cycle-related genes in lysates of MEFs from 
Jdp2KO and WT mice at the indicated times. GPDH was used as the control. (C) ChIP 
assays with JDP2-specific antibodies of lysates of Jdp2KO and WT MEFs with and 
without stimulation with serum. DNA fragments of genes for cyclin A2, p16Ink4a and 
cyclin E2 were detected by PCR with respective primers (Supplementary Table2).   
Figure 6 JDP2 negatively regulates expression of the gene for cyclin A2. (A) Schematic 
representation of the promoter of the cyclin A2 gene (nt -944 to +157) fused with a gene 
for luciferase gene. The series of deletion mutants of cyclin A2-luciferase are described 
in the text. The AP-1-like motif, AP-1 motif and CRE are indicated by a white box, a 
gray box and a black box, respectively. Point mutations in each motif are also indicated.  
(B) Reporter activities of cyclin A2-reporter deletion constructs pA2-L, pA2-M and 
pA2–N. One µg of cyclin A2 promoter-luciferase reporter plasmid and 200 ng of pSV-
luc were used for transfection of 5 x 104 Jdp2KO MEF. Six h after transfection, MEFs 
were washed, incubated for another 48 h and assayed. (C) Luciferase activities of the 
point mutants of the cyclin A2 promoter-luciferase constructs were determined as in (B).  
(D) The pSV-luc plasmid was used as the control for transfections in comparisons of 
Renilla luciferase activities of MEFs from Jdp2KO and WT mice.   
Figure 7 EMSAs with nuclear extracts (NE) with MEFs from WT and Jdp2KO mice. 
(A) NE of Jdp2KO MEFs (indicated as K), WT MEFs (indicated as W) and bovine 
serum albumin (BSA; indicated as B) were incubated with probes corresponding to the 
CRE (lanes 1-3), AP1-like sequence (AP1L; lanes 4 and 5), the AP-1 point mutant 
(mAP1, lanes 6 and 7) and AP-1 (lanes 8-15) in the presence of 10 pmol of unlabeled 
mAP1 oligodeoxynucleotide (lane 12) or 0.1 pmol, 1 pmol and 10 pmol of unlabeled 
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AP-1 oligodeoxynucleotide as competitor. Positions of shifted bands (B1) and free 
DNA probes (Free) are indicated. (B) Supershifting EMSA using NE from serum-
starved MEFs (FCS-) or 15% serum-induced MEFs (FCS+) and the DNA probe that 
corresponded to AP-1. NE from WT MEFs (W) and Jdp2KO MEFs (K) were incubated 
without (odd lanes) or with (even lanes) antibodies specific for JDP2. B2 indicates the 
super-shifted bands, N indicates nonspecifically shifted bands and X indicates 
aggregated DNA-protein complexes that remained in wells of the gel. B1 and Free 
indicate protein-DNA complexes and free DNA probes. (C) Competition and super-
shifting assays using NE of WT MEFs and the CRE DNA probe. Reaction mixtures 
containing nuclear extracts from WT MEFs were prepared without (lane 1) and with 0.1 
pmol, 1 pmol and 10 pmol of unlabeled (cold) CRE probe (lanes 2-4) and antibodies 
specific for JDP2, pJDP2, c-jun, JunB, JunD, c-Fos and ATF-2 (lanes 5 to 11), as 
indicated. B2 indicates super-shifted bands of antibody-DNA-protein complexes (B2).  
B1 and Free indicate DNA-protein complexes and un-bound CRE probe. 
Figure 8 Enhanced cyclinA2-cdk2 activity in Jdp2KO MEFs. Cells were synchronized 
and stimulated with serum as described in the text. (A) Western blots (Wes) of cyclin 
A2 and actin in whole-cell lysates (left panel) and NE (right panel). (B) Levels of cdk2-
associated cyclin A2. Whole-cell extracts from WT and Jdp2KO MEFs were 
immunoprecipitated (IP) with antibodies specific for cdk2 and then immunoprecipitates 
were subjected to SDS-PAGE (10% acrylamide) and blotted with antibodies against 
cyclin A2 (upper panel) and cdk2 (middle panel). Control Wes of whole-cell extracts 
with antibodies specific forβ-actin is indicated (lower panel). (C) Induction of cyclin 
A2-cdk2 phosphorylation of histone H1. Immunoprecipitates containing the cyclin A2-
cdk complex were isolated from whole-cell extracts (400 µg total protein) with cyclin 
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A2-specific antibodies and the histone H1-phosphorylating activity was determined in 
vitro as described in the text.   
Figure 9 Effects of ectopic JDP2 and siRNA specific for JDP2 on proliferation and the 
expression of cyclin A2. (A) Reduced proliferation of WT and Jdp2KO MEFs upon 
expression of the JDP2 expression vector. 2 x 104 WT and Jdp2KO MEFs were 
transfected with 600 ng of pcDNA4-JDP2 or pcDNA and cells were counted three days 
later by the Alamar Blue method. The relative cell number on day 0 is given as 1.  
Means of results of three experiments ± SD are shown. (B) Depressed clyclin A2 
reporter activity upon introduction of the JDP2 expression vector. We introduced 600 
ng of pJDP2 or pcDNA4 and 400 ng of pA2M or pA2mAP1 into 5 x 104 Jdp2KO MEFs, 
incubated cells for 30 h and then measured luciferase activities. (C) Depressed 
proliferation of MEFs upon infection with Adeno-JDP2. 2 x 104 WT and Jdp2KO 
MEFs were infected with recombinant adenovirus Ad-JDP2 or β-galactosidase-
encoding cDNA (Ad-cont) at an m.o.i of 1 and 10. Cells growth was counted five days 
later. (D) Depressed expression of mRNA for cyclin A2 in Jdp2KO MEFs infected with 
Ad-JDP2.  The culture and infection of cells are described in the legend to (C).  The 
expression of mRNA specific for cyclin A2 was quantitated by real-time PCR as 
described in the legend to Fig. 7A.  (E) and (F) Effects of siRNA specific for JDP2 on 
proliferation and the expression of cyclin A2.  WT MEFs (5 x 105 cells) were 
transfected with 30 pmole of siRNA specific for JDP2 (JDP2si#1 and #2)and non-
specific double-stranded RNA (CONTsi). Three days transfection, cells were harvested 
and counted (E) and total RNA was subjected to real-time PCR with primers specific for 
JDP2 or cyclin A2 (F). Levels of expression were normalized by reference to that of 
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GPDH mRNA. Data are shown as percentages, relative to results for WT MEFs as a 
negative control.   
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